Marty Tenenbaum Presents a New Path to FDA Drug Approval at PMWC

Last week, Cancer Commons founder Marty Tenenbaum spoke at the Precision Medicine World Conference (PMWC) in Durham, NC. He presented a proposal to significantly accelerate patient access to promising investigational drugs, using a new pathway to approval by the U.S. Food and Drug Administration (FDA).

The proposed Conditional Approval pathway aims to help cancer patients who may have exhausted existing options access new, promising treatments.

“It’s an idea whose time has come, and the conference provided strong validation, including some personal communications from several prominent FDA officials (past and present) who were in attendance,” Marty says. “We are currently in discussions with the FDA, and hope to be able to pilot Conditional Approval in brain cancer where the prognosis is dire.”

Learn more about the Conditional Approval pathway.